National Human Genome Research Institute (NHGRI)
275
43
53
197
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
6.2%
17 terminated/withdrawn out of 275 trials
92.1%
+5.5% vs industry average
0%
1 trials in Phase 3/4
16%
31 of 197 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (275)
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis
Role: lead
Deciphering the Genetic Architecture of Autoimmune Diseases
Role: lead
Observational Study of Advanced Data Analytics in Genetic Conditions
Role: lead
Genetic Analysis of Uncommon Disease Presentations in Non-US Populations
Role: lead
The Genetic Basis of Congenital Heart Disease in Africa
Role: lead
Supporting Just-In-Time Consent for Prenatal Screening: The INFORM Study
Role: collaborator
Developing the Family Map: Looking at Communal Coping
Role: lead
Genome Medical Sequencing for Gene Discovery
Role: lead
The NIH MINI Study: Metabolism, Infection, and Immunity in Inborn Errors of Metabolism
Role: lead
Informing Pain Treatment Using Pharmacogenomic Analysis
Role: collaborator
Reverse Phenotyping Core
Role: lead
ClinSeq: A Large-Scale Medical Sequencing Clinical Research Pilot Study
Role: lead
Genetics of Type 2 Diabetes in West Africans
Role: lead
Genetic Studies of Lysosomal Storage Disorders
Role: lead
Use of Cysteamine in the Treatment of Cystinosis
Role: lead
Analysis of Specimens From Individuals With Pulmonary Fibrosis
Role: lead
Genetic Studies in the Amish and Mennonites
Role: lead
Genomic Services Research Program
Role: lead
MK-7075 (Miransertib) in Proteus Syndrome
Role: lead
Maternal Inborn Errors of Metabolism in Pregnancy: A Pregnancy Registry Protocol
Role: lead